Inventiva Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Insider and Institutional Ownership

74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Madrigal Pharmaceuticals and Inventiva's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and Inventiva's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current ratings for Madrigal Pharmaceuticals and Inventiva, as reported by MarketBeat.com.

Madrigal Pharmaceuticals currently has a consensus target price of $167.60, suggesting a potential upside of 29.14%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Inventiva.

Summary

Madrigal Pharmaceuticals beats Inventiva on 5 of the 7 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares MacroGenics and Inventiva's net margins, return on equity and return on assets.

Insider & Institutional Ownership

95.8% of MacroGenics shares are held by institutional investors. Comparatively, 10.5% of Inventiva shares are held by institutional investors. 9.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MacroGenics and Inventiva's gross revenue, earnings per share and valuation.

Inventiva has lower revenue, but higher earnings than MacroGenics.

Analyst Ratings

This is a summary of current recommendations for MacroGenics and Inventiva, as reported by MarketBeat.com.

MacroGenics currently has a consensus target price of $33.40, suggesting a potential downside of 2.22%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Inventiva.

Summary

MacroGenics beats Inventiva on 6 of the 9 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares NGM Biopharmaceuticals and Inventiva's net margins, return on equity and return on assets.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and Inventiva's gross revenue, earnings per share and valuation.

Inventiva has lower revenue, but higher earnings than NGM Biopharmaceuticals.

Analyst Recommendations

This is a summary of current ratings for NGM Biopharmaceuticals and Inventiva, as reported by MarketBeat.com.

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 47.03%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Inventiva.

Summary

NGM Biopharmaceuticals beats Inventiva on 7 of the 10 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Amarin and Inventiva's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Amarin and Inventiva's gross revenue, earnings per share and valuation.

Inventiva has lower revenue, but higher earnings than Amarin.

Insider and Institutional Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 10.5% of Inventiva shares are owned by institutional investors. 2.8% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Amarin and Inventiva, as reported by MarketBeat.com.

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 121.86%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Amarin is more favorable than Inventiva.

Summary

Amarin beats Inventiva on 6 of the 9 factors compared between the two stocks.

Inventiva (NASDAQ:IVA) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Inventiva and Revance Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Inventiva and Revance Therapeutics' revenue, earnings per share (EPS) and valuation.

Inventiva has higher earnings, but lower revenue than Revance Therapeutics.

Institutional and Insider Ownership

10.5% of Inventiva shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inventiva and Revance Therapeutics, as provided by MarketBeat.com.

Revance Therapeutics has a consensus price target of $37.75, suggesting a potential upside of 37.77%. Given Revance Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Inventiva.

Summary

Revance Therapeutics beats Inventiva on 6 of the 9 factors compared between the two stocks.

Inventiva (NASDAQ:IVA) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Inventiva and Axsome Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Inventiva and Axsome Therapeutics' revenue, earnings per share (EPS) and valuation.

Institutional and Insider Ownership

10.5% of Inventiva shares are owned by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Inventiva and Axsome Therapeutics, as provided by MarketBeat.com.

Axsome Therapeutics has a consensus price target of $152.6667, suggesting a potential upside of 190.52%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Inventiva.

Summary

Axsome Therapeutics beats Inventiva on 5 of the 7 factors compared between the two stocks.